Stay updated on Autogene Cevumeran Combo With Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Autogene Cevumeran Combo With Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the Autogene Cevumeran Combo With Pembrolizumab in Melanoma Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision: v3.4.2 has been added. The notices about government funding and the prior Revision: v3.4.1 have been removed.SummaryDifference0.3%

- Check21 days agoChange DetectedResults were posted and key endpoints (PFS, ORR, OS, DOR) and health-related QoL data were added, with RECIST criteria and cross-over details described.SummaryDifference2%

- Check28 days agoChange DetectedAdded a Show glossary option; updated the label 'Last Update Submitted that Met QC Criteria' with new capitalization and bumped the revision to v3.4.0, while removing the older 'Last Update Submitted that met QC Criteria' and 'No FEAR Act data' labels.SummaryDifference0.2%

- Check35 days agoChange DetectedThe page now displays 'Results Submitted' indicating that trial results have been submitted, replacing the previous 'No Results Posted' status.SummaryDifference0.0%

- Check42 days agoChange DetectedPage revision updated from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check64 days agoChange DetectedThe Locations section was updated to include new regional site listings across multiple U.S. states and international regions. Some existing location subsections were removed and the revision tag updated from v3.3.2 to v3.3.3.SummaryDifference2%

Stay in the know with updates to Autogene Cevumeran Combo With Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Autogene Cevumeran Combo With Pembrolizumab in Melanoma Clinical Trial page.